Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label PET biodistribution study of zirconium-89 labeled BI 765063 or BI 770371 with ezabenlimab in advanced solid tumors
NL-OMON51904Phase 1Recruiting
- Sponsor
- IQVIA
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 765063, BI 770371 and ezabenlimab in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and melanoma (2 arms), sponsored by IQVIA. Primary endpoint: Relative change from baseline in tumor PET uptake. Started Mar 2022; status: recruiting.
02
Drugs
BI 765063BI 770371ezabenlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NL-OMON51904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51904.